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D50 (Gy) 
10-
20  
20-
30  
30-
40  
40-
50  
50-
60  
>60 
Unknown (no 
effect) 
CONV1 10.3 20.7 13.8 6.9 3.4 10.3 31.0 
CONV2 10.0 25.0 25.0 5.0 10.0 10.0 15.0 
SABR 15.2 27.3 12.1 12.1 9.1 9.1 15.2 
ΔHUmax 
(HU) 
10-
20 
20-
30 
30-
40 
40-
50 
50-
60 
>60 Unknown 
CONV1 13.8 13.8 13.8 13.8 0 13.8 31.0 
CONV2 10.0 35.0 15.0 5.0 10.0 10.0 15.0 
SABR 15.2 27.3 12.1 12.1 9.1 9.1 15.2 
Table 1 
 
 
 
Conclusions 
Baseline CT characteristics allow to identify patient-specific 
and regional differences in sensitivity for radiation-induced 
lung damage. This may be used for further treatment 
individualisation. 
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Purpose/Objective: As urinary symptoms tend to recur 
throughout follow-up, conventional method of analysis using 
cumulative peak event and time-to-event may not be optimal 
to uncover the dosimetric-symptom correlates. We assessed 
the bladder dosimetry and urinary symptom correlates using 
longitudinally-defined endpoints and using recurrent event 
models which are contrasted to the conventional analysis 
methods. 
Materials and Methods: In this study, 754 dose-surface 
information and their corresponding specific urinary 
symptoms (dysuria (D), haematuria (H), incontinence (I) and 
frequency (F)) from a cohort of patients who received 
prostate radiotherapy in the RADAR TROG 03.04 trial were 
analysed. The dosimetric-symptom correlates were analysed 
using; 1) conventional methods (cumulative incidence(peak) 
and time-to-event(Cox) analysis), 2) longitudinally-defined 
endpoint (mean symptoms), 3) recurrent event models using 
the Andersen-Gill extension of the Cox regression model for 
counting process (AG) & generalised estimating equation 
(GEE) models. Dosimetric-symptom correlates were 
contrasted for the different analytic methods. 
Results: For dysuria and haematuria, stronger relationships 
were found to the dose indices using peak and Cox models 
compared to mean symptom, AG and GEE models. Despite 
the different strength of relationship, dose-surface of the 
bladder receiving higher than 65 Gy (S65) and S70 
consistently show strong relationship to dysuria. S60 to S65 
are the most significant for Hpeak , HGEE, HCox and Hmean. None 
of the dosimetric indices satisfy the proportional hazard 
assumption for HAG. For urinary incontinence and frequency, 
stronger relationships for dosimetric indices were found for 
AG, GEE and to lesser extent mean score model while both 
peak and Cox models do not result in significant or show 
trend towards significance. S35 to S40 were found to be the 
most significant for FGEE, Fmean and FAG while S20 to S25 for IAG 
and Imean. 
Conclusions: The use of peak or time-to-event model alone is 
not optimal in assessing dose-volume correlates for certain 
urinary symptoms endpoints. Dosimetric-symptom correlates 
analysis should be supplemented by longitudinally-defined 
endpoints and/or using recurrent event models to account for 
multiple events per patient.  
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Purpose/Objective: To assess clinical and dosimetric factors 
affecting acute urinary toxicities on a large cohort of patients 
treated with external beam radiotherapy (RT) for prostate 
cancer with radical intent. 
Materials and Methods: The final dataset of a prospective 
multicentre study was considered. It included 542 patients 
treated with conventionally (74-80 Gy at 1.8-2 Gy/fr) or 
